SVB Securities analyst Mani Foroohar raised the firm’s price target on BridgeBio to $27 from $25 and keeps an Outperform rating on the shares. The price target adjustment comes ahead of the Q1 earnings report, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BBIO:
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio reports inducement grants under Nasdaq listing rule
- UBS sees fair value for BridgeBio pipeline at $36-$40 per share
- Mizuho doubts BridgeBio selling itself, says royalty deal more likely
- BridgeBio canceled conference over ‘conflict,’ Bloomberg reports
